Señales en vivo de DEST.L | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 10:55):

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom...

Stats
Volumen de hoy	254 775
Volumen promedio	546 210
Capitalización de mercado	17.53M
EPS	£0 ( 2024-04-10 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-3.07
ATR14	£0.232 (1.26%)

Destiny Pharma PLC Correlación

10 Correlaciones Más Positivas
WINE.L	0.9
GHT.L	0.889
INDV.L	0.883
DPEU.L	0.873
ONC.L	0.859
MCM.L	0.853
RMMC.L	0.842
UPGS.L	0.834
RWS.L	0.833
DGN.L	0.829

10 Correlaciones Más Negativas
CMET.L	-0.851
PEN.L	-0.827
CAMB.L	-0.818
EUZ.L	-0.804

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Destiny Pharma PLC Finanzas

Annual	2023
Ingresos:	£831 552
Beneficio Bruto:	£831 552 (100.00 %)
EPS:	£-0.0624

FY	2023
Ingresos:	£831 552
Beneficio Bruto:	£831 552 (100.00 %)
EPS:	£-0.0624

FY	2022
Ingresos:	£154 499
Beneficio Bruto:	£142 171 (92.02 %)
EPS:	£-0.0926

FY	2021
Ingresos:	£0.00
Beneficio Bruto:	£0.00 (0.00 %)
EPS:	£-0.0890

Financial Reports:

No articles found.

Destiny Pharma PLC

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, oral mucosa, and ocular infection diseases. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; the University of Southampton; Aston University; the University of Sheffield; and Cardiff University and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.